About The Study: In this cohort study, the use of glucagon-like peptide 1 receptor agonists (GLP-1RAs) semaglutide and tirzepatide was associated with a lower risk of dementia, stroke, and all-cause mortality in adults with type 2 diabetes and obesity. These findings suggest potential neuroprotective and cerebrovascular benefits of GLP-1RAs beyond glycemic control, warranting further trials to confirm these outcomes.
Corresponding author: To contact the corresponding author, James Cheng-Chung Wei, M.D., Ph.D., email jccwei@gmail.com .
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi: 10.1001/jamanetworkopen.2025.21016)
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
# # #
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time http://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2025.21016?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=071525
About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.
JAMA Network Open